Compare Docusign Inc (DOCU) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs GSK plc — how do they compare? Docusign Inc trades at $49.5 (market cap $9.43B), while GSK plc trades at $51.18 (market cap $101.55B). The key difference: GSK plc is far larger — about 10.8× Docusign Inc's market cap, and GSK plc pays a 3.5% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.
| DOCU | GSK | |
|---|---|---|
Market Cap | $9.43B | $101.55B |
Sector | Technology | Health |
52-Week High | $85.01 | $61.18 |
52-Week Low | $41.75 | $36.20 |
Enterprise Value | $8.80B | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $49.87, up 1.4% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growth to $2.98B in 2025 and net income of $1.07B, supported by consistent earnings beats. Recent partnerships with Perplexity and Slack highlight innovation in agreement management, while analyst sentiment remains mixed with a $55.40 consensus target.
Outlook is cautiously optimistic given solid profitability and strategic initiatives, but risks include pricing pressure and sector volatility. The stock presents a growth opportunity if execution continues, though investor patience is required amid competitive and macroeconomic headwinds.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
